Initiator Pharma Valuation
Is INIT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INIT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INIT (SEK8.1) is trading below our estimate of fair value (SEK13.38)
Significantly Below Fair Value: INIT is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INIT?
Other financial metrics that can be useful for relative valuation.
What is INIT's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | DKK 276.33m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does INIT's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 20x | ||
FLUO FluoGuide | 54.5x | 40.9% | SEK 496.8m |
SANION Saniona | 17.8x | 39.4% | SEK 483.9m |
HAMLET B Hamlet BioPharma | 7.2x | n/a | SEK 548.6m |
IMMU Mendus | 0.6x | 46.2% | SEK 376.2m |
INIT Initiator Pharma | 11.7x | -5.5% | SEK 428.6m |
Price-To-Book vs Peers: INIT is good value based on its Price-To-Book Ratio (11.7x) compared to the peer average (20x).
Price to Earnings Ratio vs Industry
How does INIT's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: INIT is expensive based on its Price-To-Book Ratio (11.7x) compared to the Swedish Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is INIT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 11.7x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate INIT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 8.10 | SEK 25.26 +211.9% | 5.0% | SEK 26.51 | SEK 24.01 | n/a | 2 |
Jul ’25 | SEK 10.10 | SEK 25.26 +150.1% | 5.0% | SEK 26.51 | SEK 24.01 | n/a | 2 |
Jun ’25 | SEK 10.25 | SEK 25.26 +146.4% | 5.0% | SEK 26.51 | SEK 24.01 | n/a | 2 |
May ’25 | SEK 8.92 | SEK 24.69 +176.8% | 2.8% | SEK 25.38 | SEK 23.99 | n/a | 2 |
Apr ’25 | SEK 9.10 | SEK 24.69 +171.3% | 2.8% | SEK 25.38 | SEK 23.99 | n/a | 2 |
Mar ’25 | SEK 9.00 | SEK 24.69 +174.3% | 2.8% | SEK 25.38 | SEK 23.99 | n/a | 2 |
Feb ’25 | SEK 8.14 | SEK 20.81 +155.6% | 15.3% | SEK 24.00 | SEK 17.62 | n/a | 2 |
Jan ’25 | SEK 9.24 | SEK 20.81 +125.2% | 15.3% | SEK 24.00 | SEK 17.62 | n/a | 2 |
Dec ’24 | SEK 9.28 | SEK 20.81 +124.2% | 15.3% | SEK 24.00 | SEK 17.62 | n/a | 2 |
Nov ’24 | SEK 9.28 | SEK 20.70 +123.1% | 15.8% | SEK 23.98 | SEK 17.42 | n/a | 2 |
Oct ’24 | SEK 7.66 | SEK 17.03 +122.3% | 6.0% | SEK 18.04 | SEK 16.01 | n/a | 2 |
Sep ’24 | SEK 7.68 | SEK 17.03 +121.7% | 6.0% | SEK 18.04 | SEK 16.01 | n/a | 2 |
Aug ’24 | SEK 7.20 | SEK 15.77 +119.0% | 11.3% | SEK 17.56 | SEK 13.98 | SEK 9.00 | 2 |
Jul ’24 | SEK 7.10 | SEK 15.77 +122.1% | 11.3% | SEK 17.56 | SEK 13.98 | SEK 10.10 | 2 |
Dec ’23 | SEK 6.17 | SEK 14.41 +133.6% | 2.5% | SEK 14.77 | SEK 14.06 | SEK 9.28 | 2 |
Nov ’23 | SEK 6.18 | SEK 14.41 +133.2% | 2.5% | SEK 14.77 | SEK 14.06 | SEK 9.28 | 2 |
Oct ’23 | SEK 6.95 | SEK 14.41 +107.4% | 2.5% | SEK 14.77 | SEK 14.06 | SEK 7.66 | 2 |
Sep ’23 | SEK 7.90 | SEK 14.41 +82.5% | 2.5% | SEK 14.77 | SEK 14.06 | SEK 7.68 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.